Stock Ratings / Health Care / IRWD / options

GERN (28) ACRS (19) CLYM (28) STTK (29) ⌘ Pro Terminal →

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) Options Positioning, Max Pain & Unusual Sweeps

$3.50 -3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.47

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $578.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRWD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ: IRWD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.50 (-3.31% 1D, market cap $578.3M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, IRWD ranks #171 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRWD compare to GERN and ACRS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRWD carries a Roarable C- (59/100 RQD), trailing P/E of 24.9x, gross margin of —, and ROIC of 85.0%. By comparison, GERN (Geron Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -20.2%, cap $574.6M) and ACRS (Aclaris Therapeutics Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRWD?

▼

Per IRWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001446847), Ironwood Pharmaceuticals Inc. (Class A) generated $296.2M in revenue (-15.7% YoY), $24.0M in net income, and $127.0M in free cash flow against $396.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.47 (-0.79%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 42.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+0.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRWD)Realized 20D OHLCV Swing Band: ±9.9%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY IRWD SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (29% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 42.9% FCF Margin ($127.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$3.59+1.1% Next Q

Q2 (-2Q)

Grade C+$3.63-3.3% Next Q

Q3 (-1Q)

Grade C+$3.51-0.3% Next Q

Current

Grade C-$3.50+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IRWD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, IRWD faces multiple-compression risk if 24.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.93) or 200D SMA ($3.98) invalidates the momentum regime and cuts Target Base ($3.52) toward Bear Floor ($2.75).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRWD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IRWD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.9%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IRWD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IRWD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating IRWD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on IRWD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRWD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.75%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.62H $3.62L $3.50C $3.50VOL 1.47M

RES: $4.61SUP: $3.36SMA50: $3.93SMA200: $3.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRWD Butterfly Map → + Track IRWD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.6%/yr Implied 5Y Growth

vs. -15.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRWD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRWD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRWD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRWD)

Health Care Rank #171 of 1016 ⚔️ GERN vs IRWD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRWD vs. GERN, ACRS, CLYM, STTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ironwood Pharmaceuticals Inc. (Class A) (IRWD) ranks #171 by composite RQD confidence (59/100, grade C-) and #420 by equity capitalization ($578.3M). Within this direct 5-issuer industry benchmark cohort, IRWD leads on earnings valuation at 24.9x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRWD ACTIVE Ironwood Pharmaceuticals Inc. (Class A)	C-	59/100	24.9x	—	85.0%	-3.31%	$578.3M	Benchmark Subject
GERN Geron Corporation	E	28/100	—	—	-20.2%	-5.47%	$574.6M	/gern-vs-irwd →
ACRS Aclaris Therapeutics Inc.	E	19/100	—	73.3%	-35.0%	-0.50%	$584.4M	/acrs-vs-irwd →
CLYM Climb Bio Inc.	E	28/100	—	—	-35.0%	-0.77%	$588.7M	/clym-vs-irwd →
STTK Shattuck Labs Inc.	E	29/100	—	—	-35.0%	-2.80%	$558.0M	/sttk-vs-irwd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001446847

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ironwood Pharmaceuticals Inc. (Class A) (IRWD) reported GAAP revenue of $296.2M (-15.7% vs. FY2024 revenue of $351.4M , and -33.1% cumulative change since FY2023) , GAAP net income of $24.0M, operating cash flow of $127.0M, and free cash flow of $127.0M (+22.8% YoY). On the balance sheet, IRWD closed FY2025 with $396.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$296.2M	$24.0M	$127.0M	$127.0M	$396.9M	—
FY2024 (FY)	2024-12-31	$351.4M	$880.0K	$103.5M	$103.4M	$350.9M	—
FY2023 (FY)	2023-12-31	$442.7M	-$1.03B	$183.4M	$183.4M	—	—

3. IRWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IRWD compare to GERN and ACRS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IRWD?

Where is IRWD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRWD last traded at $3.50 (-3.31% on volume of 1,470,631 shares), positioning the stock -10.94% below its 50-day simple moving average ($3.93) and -12.06% below its 200-day simple moving average ($3.98). Across its 52-week range of $1.76 to $5.78, IRWD sits at the 43.3% percentile with a 14-day RSI of 41.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($3.15 to $3.85).

IRWD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IRWD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for IRWD.

Direct Sub-Reports: IRWD RQD Cockpit IRWD 12M Forecast IRWD Earnings & Move IRWD Dividends & DRIP IRWD Insiders & 13F IRWD Whale Options IRWD Profit Sankey IRWD News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IRWD — Ironwood Pharmaceuticals Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:34:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IRWD scores 63 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine: 15 / 20. Per the Roarable RQD rating, this reflects ROIC of 85% and an FCF yield of 21.23%. These are the strongest cash-generation readings in the data set and are the main upside support for the score.
Whale 13F Flow: 7 / 20. Per the Roarable RQD rating, this covers institutional accumulation and options positioning. The score is weak, indicating limited evidence of sustained institutional conviction in the source data.
Insider Conviction: 17 / 20. Per the Roarable RQD rating, this reflects an SEC Form 4 and Congressional PTR cluster flow. It is the highest pillar score and signals comparatively strong insider-side conviction, though the underlying trade-level detail is not included in the source data.
Macro Regime Fit: 12 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The score indicates market-matching volatility rather than a defensive or high-beta profile.
Forensic Balance Sheet: 12 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 7/9, and Debt/Equity is 0.5. The Altman reading is in a distress-signal range, partially offset by a relatively strong Piotroski reading.

For a prospective investor, the rating describes a mixed picture: exceptional reported cash-return metrics and strong insider-flow scoring are weighed against weak institutional flow and a low Altman Z-Score. The valuation tradeoff is visible in the market data: trailing P/E of 24.9 and forward P/E of 23.2 sit alongside an EV/EBITDA of 3.9, so the multiple picture depends heavily on which earnings measure is emphasized. The rating's "Hold" verdict reflects this balance rather than a directional call. This is an analytical framing, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
3.62	$598.2M	24.9	23.2	3.9	0.15	0%	1.0	$1.61 - $5.78	85%

Business

Ironwood Pharmaceuticals Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it has a market capitalization of $0.6B. The source data does not describe its products, customers, or specific revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$296.2M	$98.5M	$24.0M	N/A	$127.0M	$215.5M	N/A
FY 2024	$351.4M	$93.1M	$0.9M	N/A	$103.4M	$88.6M	N/A
FY 2023	$442.7M	$-945.4M	$-1031.6M	N/A	$183.4M	N/A	N/A

Per the SEC financials, revenue declined from $442.7M in FY 2023 to $351.4M in FY 2024 and $296.2M in FY 2025, while operating income turned positive in FY 2024 and remained positive at $98.5M in FY 2025. Per the market data, operating margin is 33.3% and net margin is 8.1%, with ROIC at 85%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 7/9, a combination that pairs a weak distress-model reading with a relatively strong accounting-quality reading. Per the Roarable RQD rating, Debt/Equity is 0.5.

Open Questions

What are the outcomes and timing of the second apraglutide trial, and how does the source data quantify its importance to the company's cash flows?
What is the nature and timing of the CEO transition, and is there a disclosed succession plan?
What drives the gap between the 85% ROIC and the 8.1% net margin, and how sustainable is FY 2025 operating income given revenue decline?
What debt obligations sit behind the 0.5 Debt/Equity ratio, given that debt values are not reported in the financials?
What specific insider and institutional transactions underlie the RQD insider-conviction and whale-flow pillar scores?

IRWD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ironwood Pharmaceuticals Inc. (Class A) (IRWD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IRWD Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 17h ago

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Seeking Alpha report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com • 20h ago

Ironwood Pharmaceuticals stock falls on CEO transition news

Investing.com report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 23h ago

Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

Benzinga report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Bank of America reports an Ironwood Pharmaceuticals (IRWD) stake with no sole voting power.

Stock Titan report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Ironwood Pharmaceuticals stock heads toward November 9 results

ad-hoc-news.de report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Ironwood Pharmaceuticals (IRWD) Slips 1.29% to $3.82 as Shares Drift Toward Support - Bull Pennant

https://www.siam.in/ report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

Ironwood Pharmaceuticals (IRWD) Gains 2.29% to $3.58 as Buyers Test Resistance - Mutual Fund Flow

https://www.dars.gov.et/ report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 5d ago

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

BOSTON, October 28, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5,

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IRWD Bull vs. Bear Conversation Board — What's Your Call at $3.50?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRWD 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.91 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IRWD (C • RQD 63/100) a Buy at $3.62?

Welcome to the IRWD (Ironwood Pharmaceuticals Inc. (Class A)) Roar Pit. Current RQD Composite is 63/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.00 (-17.1%)

Spot @ $3.62

Pump the brakes on IRWD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IRWD, but look at what you are paying: 24.9x trailing P/E with tightening sector spreads. Unless Ironwood Pharmaceuticals Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.34 (+19.9%)

Spot @ $3.62

IRWD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IRWD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.62 (52-wk range $1.61 - $5.78), any beat on forward guidance forces shorts and underweight funds to chase.